What one share of Structure Therapeutics holds
We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (“GPCRs”).
Structure Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.07 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.12 |
| Cash and investments | $1.28 |
| Book value | $6.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$5.51 | — | — | — | −$10.94 |
| 2023 | — | −$0.81 | $0.02 | −$0.74 | — | $3.25 |
| 2024 | — | −$0.78 | $0.01 | −$0.75 | — | $5.03 |
| 2025 | — | −$0.80 | $0.02 | −$1.27 | — | $7.14 |
Common questions about Structure Therapeutics
How much does one share of Structure Therapeutics earn?
Over the last 12 months, Structure Therapeutics lost $1.07 for each share.
Does Structure Therapeutics pay a dividend?
Structure Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Structure Therapeutics’s book value per share?
Structure Therapeutics’s book value is $6.34 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Structure Therapeutics have?
Each share of Structure Therapeutics has $1.28 of cash and investments, as of June 30, 2026.
What is Structure Therapeutics’s free cash flow per share?
−$1.12 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Structure Therapeutics bought back shares?
Structure Therapeutics’s share count rose about 1753% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.